<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The enzymatic activity of acetylcholinesterase (AchE) in the cerebrospinal fluid (CSF) is considered to be a marker of central cholinergic neuron integrity </plain></SENT>
<SENT sid="1" pm="."><plain>Then, we evaluated CSF AchE activity in 90 cases of <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurological diseases</z:e> involving cholinergic system and their related disease, and 28 control cases without central organic lesions or abnormal findings in routine CSF study </plain></SENT>
<SENT sid="2" pm="."><plain>AchE activity was evaluated according to Ellman's method using acetylthiocholine <z:chebi fb="1" ids="16382">iodide</z:chebi> as a substrate and tetraisopropyl-pyrophosphoramide, a specific inhibitor of butyrylocholinesterase </plain></SENT>
<SENT sid="3" pm="."><plain>CSF AchE of Alzheimer type <z:hpo ids='HP_0000726'>dementia</z:hpo> (AD/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SDAT</z:e>, N = 12: 21.9 +/- 4.7 nmol/ml/min) showed no significant change from those of both control group (22.1 +/- 3.9) and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (9: 21.7 +/- 6.7) </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="C0015371" disease_type="Disease or Syndrome" abbrv="">extrapyramidal diseases</z:e>, reduction of the activity was observed in Huntington's <z:hpo ids='HP_0002072'>chorea</z:hpo> (HC, 4: 16.3 +/- 1.4) and <z:e sem="disease" ids="C0038868" disease_type="Disease or Syndrome" abbrv="PSNP1">progressive supranuclear palsy</z:e> (PSP, 4: 17.6 +/- 1.7), whereas <z:mpath ids='MPATH_458'>normal</z:mpath> activity was shown in <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>, 19: 22.5 +/- 4.6), dentatorubropallidoluysian <z:mpath ids='MPATH_127'>atrophy</z:mpath> (DRPLA, 4: 22.6 +/- 4.2) and <z:e sem="disease" ids="C0270733" disease_type="Disease or Syndrome" abbrv="">striatonigral degeneration</z:e> (SND, 4: 20.4 +/- 4.3) </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:hpo ids='HP_0002542'>olivopontocerebellar atrophy</z:hpo> (OPCA, N = 16), we disclosed reduced CSF AchE activity (15.8 +/- 2.4) which had significant correlations with the <z:mpath ids='MPATH_127'>atrophy</z:mpath> of the pontine base (r = 0.6017, p less than 0.02) and cerebellar vermis (r = 0.5450, p less than 0.05) in MRI </plain></SENT>
<SENT sid="6" pm="."><plain>AchE activity in <z:hpo ids='HP_0008278'>cerebellar cortical atrophy</z:hpo> (CCA, 5: 20.6 +/- 2.2) remained within the control values </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> activity was demonstrated in both <z:hpo ids='HP_0007354'>amyotrophic lateral sclerosis</z:hpo> (6: 24.3 +/- 7.3) and <z:hpo ids='HP_0007269'>spinal muscular atrophy</z:hpo> (4: 22.9 +/- 3.9).(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>